As part of the Janssen Diversity, Equity, and Inclusion in Clinical Trials team, Lisa Lewis helps drive the inclusion of underserved and/or underrepresented populations in oncology clinical trials. Lisa has 25 years of experience in Oncology Preclinical Research, Early and Late Clinical Development, Clinical Operations, Medical Affairs and Public Health, and Oncology Therapeutics.

Lisa has worked directly with cancer patients and clinical trial participants at academic and community sites. She has held Director, Associate Director, Senior Clinical Scientist, Global Trial Leader, and Consultant roles at companies including Novartis Oncology, Bristol-Myers Squibb, AstraZeneca, and G1 Therapeutics.

Lisa received her BS in Biology (Pre-medicine) from Stony Brook University and MPH with a concentration in Health Informatics from New York Medical College. She is continuing her studies toward an MS in Bioethics at The Harvard Medical School Center for Bioethics in the Fall of 2023.

Kim Fookes has 29+ years of experience working in clinical research. Prior to being named the Global Head of DICT, Kim was responsible for all US clinical trial deliverables across Novartis’ portfolio, including early and late phase oncology and non-oncology.  She joined Novartis from AbbVie where she was the Head of Site Management & Monitoring, overseeing Global Site Management.  While at AbbVie, Kim also managed operations for the Global Medical Affairs’ Therapeutic Areas and US Medical Affairs.  Prior to AbbVie, she worked at Takeda, CROs, and Site Research Centers.

In her role as Global Head of DICT, she is working to imbed diversity across the R&D continuum so teams can consider diverse patient populations very early, including phase I trials.

Sandra Amaro, MBA, is the Head of Clinical Trial Diversity Center of Excellence at Pfizer, located in Groton, CT. In this role, she leads a group of Clinical Trial Diversity Leads who are accountable for enabling Pfizer’s Clinical Study Teams in the effort to increase equity and inclusion in clinical trials. Within her role, Sandra is also responsible for helping elevate the topic of diversity both within Pfizer and externally. In 2021, Sandra was appointed as TransCelerate’s Workstream Lead for their Diversity of Participates in Clinical Trials Workstream.

Sandra has been with Pfizer since May 2004, where she has held different leadership positions within Clinical Development and Operations and Global Clinical Supply.

Sandra received her Bachelor of Science degree in Business and Leadership from Albertus Magnus College, and her Master of Business Administration degree from the University of Rhode Island.

Sherman Womack holds a leadership position as a Deacon at the Metropolitan Baptist Church of Boston, which was first opened in 1935. Furthermore, Sherman Womack is a prostate cancer survivor who is a member of PHEN’s Survivor Network.

In 2008 and 2018, he participated in PHEN Survivor Roundtable Discussions. At these roundtables, Sherman explained his own personal cancer journey and the outreach efforts he has participated in to spread prostate cancer awareness.

Sherman Womack has worked at the Lynn Fire Department and resides in Peabody, Massachusetts.

Dewayne Charleston is a former judge who is currently the publisher of Prairie View magazine, which is a monthly publication serving central Texas and the Prairie View A&M University community. He was diagnosed with prostate cancer in 2009 at the age of 46 and has undergone three surgeries and seven different therapies, including participation in two clinical trials.

 He was featured in the Tubi documentary The Silent Killer: Prostate Cancer in the African American Community. Dewayne Charleston is the proud father of Christian and Christopher

After completing a bachelor’s and a master’s degree at Harvard, Richard Lee, MD, PhD, then completed his medical school (M.D.) and graduate school (Ph.D.) training at the Albert Einstein College of Medicine in the Bronx, New York. He came to Mass General Hospital (MGH) for internal medicine residency training and then completed a medical oncology fellowship through the Dana-Farber Cancer Institute/MGH joint program. During that time, he performed basic science research at the Whitehead Institute of MIT.